Pfizer, Concerto HealthAI join up for precision medicine partnership

Pfizer is working with Boston-based Concerto HealthAI for a collaboration that will apply Concerto's eurekaHealth artificial intelligence technology to precision oncology research. WHY IT MATTERS The partnership will use the AI platform to gain faster actionable insights for Pfizer's investigational therapies and commercialized therapeutics for treatment of solid tumors and hematologic malignancies, officials said. Romesh Wadhwani, executive chairman of Concerto HealthAI said his company's technology would be valuable to Pfizer in "finding and acting on meaningful insights in key cancer subpopulations." Much of the data for the initiative will come from clinical practices participating in the American Society of Clinical Oncology's CancerLinQ initiative; researchers will explore potential study designs for real-world data to develop therapeutics that are both pre- and post-approval, according to Concerto HealthAI, building on similar work done in collaboration with the U.S. Food and Drug Administration. A joint steering committee from both companies will oversee the work, with initial research expected early next year.